您的位置: 首页 > 农业专利 > 详情页

MODULATION DE PCSK9 ET DE LDLR PAR INHIBITION DE DRP1
专利权人:
The Brigham and Women's Hospital; Inc.
发明人:
AIKAWA, Elena,ROGERS, Maximillian,AIKAWA, Masanori
申请号:
EP17851394
公开号:
EP3512527A4
申请日:
2017.09.12
申请国别(地区):
EP
年份:
2020
代理人:
摘要:
Provided herein are methods for reducing levels of blood cholesterol, low-density lipoprotein (LDL), and/or the treatment of diseases associated with high cholesterol, hyperlipidemia, dyslipidemia, or high levels of low-density lipoprotein (LDL), wherein the methods comprise administering a DRP1 inhibitor to a subject in need thereof. In certain embodiments, the subject is selected for treatment as described herein when the subject exhibits intolerance to conventional statin therapy. Also contemplated herein are the use of DRP1 inhibitors in the treatment of cancer and inflammatory disease.
来源网站:
中国工程科技知识中心
来源网址:
http://www.ckcest.cn/home/

意 见 箱

匿名:登录

个人用户登录

找回密码

第三方账号登录

忘记密码

个人用户注册

必须为有效邮箱
6~16位数字与字母组合
6~16位数字与字母组合
请输入正确的手机号码

信息补充